OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of February 24, 2026, OCS stock price climbed to $29.63 with 235,224 million shares trading.

OCS has a beta of 0.70, meaning it tends to be less sensitive to market movements. OCS has a correlation of 0.06 to the broad based SPY ETF.

OCS has a market cap of $1.71 billion. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $303,761 in Revenue and -$.40 earnings per share. This beat revenue expectation by $53,761 and exceeded earnings estimates by $.10.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, SMLV, GWX.

OCS has outperformed the market in the last year with a price return of +38.4% while the SPY ETF gained +15.8%. OCS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +53.8% and +4.5%, respectively, while the SPY returned +4.6% and -1.0%, respectively.

OCS support price is $27.86 and resistance is $29.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.